← Leaderboards
Bruce F Smith
Auburn University At Auburn
$1,980,036
Attributed
$2,807,840
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $397.7K · FY2006–24$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,766,649 · 3
FDA$41,191 · 1
By mechanism
R01$1,349,134 · 2
T32$1,241,706 · 1
R03$217,000 · 1
Top collaborators
- Taffye Benson Clayton4 shared
- Melody L Russell4 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoGene TherapyHerpes Simplex InfectionsHuman DiseaseAdenovirus VectorCancerousAffectGeneticAnimalsHome EnvironmentB-Cell LymphomasCellsClinical TrialsDendritic CellsDiagnosisDiagnostic ImagingCanis FamiliarisAdenovirusesEvaluationCapsidFiberCd40 LigandGene DeliveryLabel
Grant awards (13)
G-RISE at Auburn University$397,687
T32 · FY2024 · GM · contact PI
G-RISE at Auburn University$384,356
T32 · FY2023 · GM · contact PI
G-RISE at Auburn University$283,135
T32 · FY2022 · GM · contact PI
G-RISE at Auburn University$176,528
T32 · FY2021 · GM · contact PI
A Relative Expectation of Efficacy Trial of MMX Peptide in Canine Melanoma$41,191
R01 · FY2015 · FD · contact PI
Targeted Gene Therapy for Lymphoma$267,784
R01 · FY2010 · CA · contact PI
Targeted Gene Therapy for Lymphoma$263,186
R01 · FY2009 · CA · contact PI
Targeted Gene Therapy for Lymphoma$256,177
R01 · FY2008 · CA · contact PI
Targeted Gene Therapy for Lymphoma$254,310
R01 · FY2007 · CA · contact PI
Targeted Gene Therapy for Lymphoma$266,486
R01 · FY2006 · CA · contact PI
Molecular identification of canine dystrophinopathies$72,500
R03 · FY2004 · AR
Molecular identification of canine dystrophinopathies$72,500
R03 · FY2003 · AR
Molecular identification of canine dystrophinopathies$72,000
R03 · FY2002 · AR